{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:27:07Z","timestamp":1781209627475,"version":"3.54.1"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00115-018-0629-7","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T07:44:37Z","timestamp":1539935077000},"page":"472-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antipsychotikaassoziierte motorische Symptome bei schizophrenen Psychosen \u2013 Teil\u00a03","Antipsychotic-induced motor symptoms in schizophrenic psychoses\u2014Part\u00a03"],"prefix":"10.1007","volume":"90","author":[{"given":"D.","family":"Hirjak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"Kubera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bienentreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"Thomann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. C.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,19]]},"reference":[{"issue":"1","key":"629_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00115-017-0375-2","volume":"89","author":"D Hirjak","year":"2018","unstructured":"Hirjak D, Northoff G, Thomann PA, Kubera KM, Wolf RC (2018) Genuine motor phenomena in schizophrenic psychoses: Theoretical background and definition of context. Nervenarzt 89(1):44\u201350. https:\/\/doi.org\/10.1007\/s00115-017-0375-2","journal-title":"Nervenarzt"},{"issue":"12","key":"629_CR2","first-page":"550","volume":"28","author":"M Schonecker","year":"1957","unstructured":"Schonecker M (1957) Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt 28(12):550\u2013553","journal-title":"Nervenarzt"},{"key":"629_CR3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-642-18533-5_2","volume-title":"Bewegungsst\u00f6rungen bei psychischen Erkrankungen","author":"M Dose","year":"2004","unstructured":"Dose M (2004) Neuroleptika-induzierte vs. genuine Bewegungsst\u00f6rungen. In: Jahn T (Hrsg) Bewegungsst\u00f6rungen bei psychischen Erkrankungen. Springer, Heidelberg, S 29\u201359"},{"issue":"2","key":"629_CR4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000339456","volume":"66","author":"S Walther","year":"2012","unstructured":"Walther S, Strik W (2012) Motor symptoms and schizophrenia. Neuropsychobiology 66(2):77\u201392","journal-title":"Neuropsychobiology"},{"issue":"1","key":"629_CR5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbs152","volume":"40","author":"V Peralta","year":"2014","unstructured":"Peralta V et al (2014) Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs. Schizophr Bull 40(1):214\u2013224","journal-title":"Schizophr Bull"},{"key":"629_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/acps.12038","volume":"127","author":"M Fink","year":"2013","unstructured":"Fink M (2013) Rediscovering catatonia: the biography of a\u00a0treatable syndrome. Acta Psychiatr Scand Suppl 127:1\u201347","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"7","key":"629_CR7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s001150050485","volume":"70","author":"MR Lemke","year":"1999","unstructured":"Lemke MR (1999) Motor signs of depression. Nervenarzt 70(7):600\u2013612","journal-title":"Nervenarzt"},{"issue":"3","key":"629_CR8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/JCP.0b013e31828f62b0","volume":"33","author":"V Peralta","year":"2013","unstructured":"Peralta V et al (2013) Phenomenological differences between spontaneous and drug-related extrapyramidal syndromes in patients with schizophrenia-spectrum disorders. J\u00a0Clin Psychopharmacol 33(3):438\u2013440","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"629_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.schres.2015.10.022","volume":"169","author":"D Hirjak","year":"2015","unstructured":"Hirjak D, Thomann PA, Kubera KM, Wolf ND, Sambataro F, Wolf RC (2015) Motor dysfunction within the schizophrenia-spectrum: a dimensional step towards an underappreciated domain. Schizophr Res 169(1\u20133):217\u2013233. https:\/\/doi.org\/10.1016\/j.schres.2015.10.022","journal-title":"Schizophr Res"},{"issue":"7","key":"629_CR10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00115-016-0136-7","volume":"88","author":"D Hirjak","year":"2017","unstructured":"Hirjak D, Thomann PA, Northoff G, Kubera KM, Wolf RC (2017) Deutsche Version der Northoff Catatonia Rating Scale (NCRS-dv) \u2013 Ein validiertes Messinstrument zur Erfassung katatoner Symptome. Nervenarzt 88(7):787\u2013796. https:\/\/doi.org\/10.1007\/s00115-016-0136-7","journal-title":"Nervenarzt"},{"key":"629_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-018-0582-5","author":"D Hirjak","year":"2018","unstructured":"Hirjak D, Kubera KM, Bienentreu S, Thomann PA, Wolf RC (2018) Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 1: dystonia, akathisia und parkinsonism. Nervenarzt. https:\/\/doi.org\/10.1007\/s00115-018-0582-5","journal-title":"Nervenarzt"},{"key":"629_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-018-0581-6","author":"D Hirjak","year":"2018","unstructured":"Hirjak D, Sartorius A, Kubera KM, Wolf RC (2018) Antipsychotic-induced motor symptoms in schizophrenic psychoses-part\u00a02: catatonic symptoms and neuroleptic malignant syndrome. Nervenarzt. https:\/\/doi.org\/10.1007\/s00115-018-0581-6","journal-title":"Nervenarzt"},{"issue":"3","key":"629_CR13","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.4088\/JCP.16r10832","volume":"78","author":"M Carbon","year":"2017","unstructured":"Carbon M, Hsieh CH, Kane JM, Correll CU (2017) Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J\u00a0Clin Psychiatry 78(3):e264\u2013e278. https:\/\/doi.org\/10.4088\/JCP.16r10832","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"1","key":"629_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/JCP.0000000000000250","volume":"35","author":"S Ryu","year":"2015","unstructured":"Ryu S et al (2015) Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a\u00a0cross-sectional and retrospective study. J\u00a0Clin Psychopharmacol 35(1):13\u201321","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"629_CR15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.4088\/JCP.tv17016ah4c","volume":"78","author":"CU Correll","year":"2017","unstructured":"Correll CU, Kane JM, Citrome LL (2017) Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J\u00a0Clin Psychiatry 78(8):1136\u20131147","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"629_CR16","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/08039488.2016.1164245","volume":"70","author":"M Parksepp","year":"2016","unstructured":"Parksepp M et al (2016) Prevalence of neuroleptic-induced movement disorders: an 8\u2011year follow-up study in chronic schizophrenia inpatients. Nord J Psychiatry 70(7):498\u2013502","journal-title":"Nord J Psychiatry"},{"issue":"5","key":"629_CR17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1176\/ajp.148.5.661","volume":"148","author":"V Khot","year":"1991","unstructured":"Khot V, Wyatt RJ (1991) Not all that moves is tardive dyskinesia. Am J Psychiatry 148(5):661\u2013666","journal-title":"Am J Psychiatry"},{"issue":"3","key":"629_CR18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0925-4927(91)90007-D","volume":"40","author":"CC Mion","year":"1991","unstructured":"Mion CC et\u00a0al (1991) MRI abnormalities in tardive dyskinesia. Psychiatry Res 40(3):157\u2013166","journal-title":"Psychiatry Res"},{"issue":"9","key":"629_CR19","doi-asserted-by":"crossref","first-page":"e1426","DOI":"10.4088\/JCP.tv17016tx1c","volume":"78","author":"CU Correll","year":"2017","unstructured":"Correll CU (2017) Epidemiology and prevention of tardive dyskinesia. J\u00a0Clin Psychiatry 78(9):e1426","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"629_CR20","first-page":"486","volume":"39","author":"NR Schooler","year":"1982","unstructured":"Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39(4):486\u2013487","journal-title":"Arch Gen Psychiatry"},{"key":"629_CR21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1192\/bjp.159.3.440a","volume":"159","author":"PN Harten van","year":"1991","unstructured":"van Harten PN (1991) Tardive dystonia: male:female ratio. Br J Psychiatry 159:440","journal-title":"Br J Psychiatry"},{"issue":"12","key":"629_CR22","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4088\/JCP.v67n1212","volume":"67","author":"PN Harten van","year":"2006","unstructured":"van Harten PN et al (2006) Incidence of tardive dyskinesia and tardive dystonia in African caribbean patients on long-term antipsychotic treatment: the Curacao Extrapyramidal Syndromes Study V. J\u00a0Clin Psychiatry 67(12):1920\u20131927","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"629_CR23","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/oxfordjournals.schbul.a033415","volume":"25","author":"PN Harten van","year":"1999","unstructured":"van Harten PN, Kahn RS (1999) Tardive dystonia. Schizophr Bull 25(4):741\u2013748","journal-title":"Schizophr Bull"},{"issue":"2\u20133","key":"629_CR24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0920-9964(95)00096-8","volume":"19","author":"PN Harten van","year":"1996","unstructured":"van Harten PN et\u00a0al (1996) The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I. Schizophr Res 19(2\u20133):195\u2013203","journal-title":"Schizophr Res"},{"key":"629_CR25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2018.02.007","volume":"389","author":"A D\u2019Abreu","year":"2018","unstructured":"D\u2019Abreu A, Akbar U, Friedman JH (2018) Tardive dyskinesia: epidemiology. J\u00a0Neurol Sci 389:17\u201320","journal-title":"J Neurol Sci"},{"key":"629_CR26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1192\/bjp.bp.106.035063","volume":"191","author":"RA Rosenheck","year":"2007","unstructured":"Rosenheck RA (2007) Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br J Psychiatry 191:238\u2013245","journal-title":"Br J Psychiatry"},{"issue":"1","key":"629_CR27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1176\/ajp.2007.164.1.170","volume":"164","author":"RA Rosenheck","year":"2007","unstructured":"Rosenheck RA (2007) Comment on \u201ctardive dyskinesia circa\u00a02006\u201d. Am J Psychiatry 164(1):170 (author reply 170)","journal-title":"Am J Psychiatry"},{"issue":"9","key":"629_CR28","doi-asserted-by":"crossref","first-page":"e1428","DOI":"10.4088\/JCP.tv17016tx2c","volume":"78","author":"JM Kane","year":"2017","unstructured":"Kane JM (2017) Assessing patients for tardive dyskinesia. J\u00a0Clin Psychiatry 78(9):e1428","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"629_CR29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","volume":"193","author":"DD Miller","year":"2008","unstructured":"Miller DD et al (2008) Extrapyramidal side-effects of antipsychotics in a\u00a0randomised trial. Br J Psychiatry 193(4):279\u2013288","journal-title":"Br J Psychiatry"},{"issue":"4","key":"629_CR30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","volume":"71","author":"SW Woods","year":"2010","unstructured":"Woods SW et\u00a0al (2010) Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a\u00a0prospective cohort study. J\u00a0Clin Psychiatry 71(4):463\u2013474","journal-title":"J Clin Psychiatry"},{"key":"629_CR31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-3-642-83654-1_19","volume-title":"Katatone und dyskinetische Syndrome","author":"J Tegeler","year":"1989","unstructured":"Tegeler J (1989) Klinik der Sp\u00e4tdyskinesien. In: Hippius H, R\u00fcther E, Schmau\u00df M (Hrsg) Katatone und dyskinetische Syndrome. Springer, Heidelberg, S\u00a0197\u2013211"},{"issue":"2","key":"629_CR32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00002826-198306000-00003","volume":"6","author":"D Tarsy","year":"1983","unstructured":"Tarsy D (1983) History and definition of tardive dyskinesia. Clin Neuropharmacol 6(2):91\u201399","journal-title":"Clin Neuropharmacol"},{"key":"629_CR33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13034-017-0192-1","volume":"11","author":"LJ Kalverdijk","year":"2017","unstructured":"Kalverdijk LJ et al (2017) A multi-national comparison of antipsychotic drug use in children and adolescents, 2005\u20132012. Child Adolesc Psychiatry Ment Health 11:55","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"3","key":"629_CR34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/cap.2017.0079","volume":"28","author":"X Zhu","year":"2018","unstructured":"Zhu X et al (2018) Comparison of unlicensed and off-label use of Antipsychotics prescribed to child and adolescent psychiatric outpatients for treatment of mental and behavioral disorders with different guidelines: the China food and drug administration versus the FDA. J\u00a0Child Adolesc Psychopharmacol 28(3):216\u2013224","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"629_CR35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/YIC.0000000000000216","volume":"33","author":"S Deng","year":"2018","unstructured":"Deng S et al (2018) Off-label antidepressant prescription in pediatric outpatients based on China Food and Drug Administration and Food and Drug Administration regulations: a\u00a0Chinese retrospective study. Int Clin Psychopharmacol 33(3):172\u2013179","journal-title":"Int Clin Psychopharmacol"},{"key":"629_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13607863.2017.1401583","volume":"20","author":"H Bakouni","year":"2017","unstructured":"Bakouni H, Berbiche D, Vasiliadis HM (2017) Off-label use of antipsychotics and associated factors in community living older adults. Aging Ment Health 20:1\u20138. https:\/\/doi.org\/10.1080\/13607863.2017.1401583","journal-title":"Aging Ment Health"},{"issue":"5","key":"629_CR37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/YIC.0000000000000127","volume":"31","author":"U Albert","year":"2016","unstructured":"Albert U et al (2016) Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a\u00a0systematized review. Int Clin Psychopharmacol 31(5):249\u2013258","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"629_CR38","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4088\/JCP.13m08857","volume":"76","author":"BE Cohen","year":"2015","unstructured":"Cohen BE et\u00a0al (2015) Antipsychotic prescriptions in Iraq and Afghanistan veterans with posttraumatic stress disorder in Department of Veterans Affairs healthcare, 2007\u20132012. J\u00a0Clin Psychiatry 76(4):406\u2013412","journal-title":"J Clin Psychiatry"},{"key":"629_CR39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12991-018-0176-4","volume":"17","author":"C Lucke","year":"2018","unstructured":"Lucke C et al (2018) Off-label prescription of psychiatric drugs by non-psychiatrist physicians in three general hospitals in Germany. Ann Gen Psychiatry 17:7","journal-title":"Ann Gen Psychiatry"},{"issue":"2","key":"629_CR40","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004714-200004000-00011","volume":"20","author":"J Ballesteros","year":"2000","unstructured":"Ballesteros J, Gonzalez-Pinto A, Bulbena A (2000) Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a\u00a0meta-analysis of seven independent studies. J\u00a0Clin Psychopharmacol 20(2):188\u2013194","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"629_CR41","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.4088\/JCP.v69n1008","volume":"69","author":"H Ascher-Svanum","year":"2008","unstructured":"Ascher-Svanum H et al (2008) Tardive dyskinesia and the 3\u2011year course of schizophrenia: results from a\u00a0large, prospective, naturalistic study. J\u00a0Clin Psychiatry 69(10):1580\u20131588","journal-title":"J Clin Psychiatry"},{"key":"629_CR42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00496058","volume":"64","author":"GM Simpson","year":"1979","unstructured":"Simpson GM, Lee JH, Zoubok B, Gardos G (1979) A\u00a0rating scale for tardive dyskinesia. Psychopharmacology 64:171\u2013179","journal-title":"Psychopharmacology"},{"key":"629_CR43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","volume":"389","author":"R Bhidayasiri","year":"2018","unstructured":"Bhidayasiri R et\u00a0al (2018) Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J\u00a0Neurol Sci 389:67\u201375","journal-title":"J Neurol Sci"},{"key":"629_CR44","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.neubiorev.2017.06.007","volume":"80","author":"PN Harten van","year":"2017","unstructured":"van Harten PN et\u00a0al (2017) The clinical and prognostic value of motor abnormalities in psychosis, and the importance of instrumental assessment. Neurosci Biobehav Rev 80:476\u2013487","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"629_CR45","first-page":"87","volume":"28","author":"MJ Harris","year":"1992","unstructured":"Harris MJ et\u00a0al (1992) High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. Psychopharmacol Bull 28(1):87\u201392","journal-title":"Psychopharmacol Bull"},{"key":"629_CR46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1192\/bjp.171.2.148","volume":"171","author":"MP Caligiuri","year":"1997","unstructured":"Caligiuri MP et\u00a0al (1997) Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry 171:148\u2013153","journal-title":"Br J Psychiatry"},{"issue":"4","key":"629_CR47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF02246639","volume":"123","author":"JS Paulsen","year":"1996","unstructured":"Paulsen JS et\u00a0al (1996) Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a\u00a0prospective longitudinal study. Psychopharmacology (Berl) 123(4):307\u2013314","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"629_CR48","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archpsyc.1995.03950210050010","volume":"52","author":"DV Jeste","year":"1995","unstructured":"Jeste DV et\u00a0al (1995) Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 52(9):756\u2013765","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"629_CR49","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1176\/jnp.3.3.334","volume":"3","author":"D Rogers","year":"1991","unstructured":"Rogers D (1991) Catatonia: a\u00a0contemporary approach. J\u00a0Neuropsychiatry Clin Neurosci 3(3):334\u2013340","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"4","key":"629_CR50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/YCT.0b013e3181fe28bd","volume":"26","author":"A Francis","year":"2010","unstructured":"Francis A et\u00a0al (2010) Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. J\u00a0Ect 26(4):246\u2013247","journal-title":"J Ect"},{"issue":"7","key":"629_CR51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1017\/S1092852900013377","volume":"5","author":"G Northoff","year":"2000","unstructured":"Northoff G (2000) Brain imaging in catatonia: current findings and a\u00a0pathophysiologic model. Cns Spectr 5(7):34\u201346","journal-title":"Cns Spectr"},{"issue":"5","key":"629_CR52","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1017\/S0140525X02000109","volume":"25","author":"G Northoff","year":"2002","unstructured":"Northoff G (2002) What catatonia can tell us about \u201ctop-down modulation\u201d: a\u00a0neuropsychiatric hypothesis. Behav Brain Sci 25(5):555\u2013577 (discussion 578\u2013604)","journal-title":"Behav Brain Sci"},{"key":"629_CR53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","volume":"389","author":"M Solmi","year":"2018","unstructured":"Solmi M et\u00a0al (2018) Clinical risk factors for the development of tardive dyskinesia. J\u00a0Neurol Sci 389:21\u201327","journal-title":"J Neurol Sci"},{"issue":"2\u20133","key":"629_CR54","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","volume":"76","author":"G Chouinard","year":"2005","unstructured":"Chouinard G, Margolese HC (2005) Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 76(2\u20133):247\u2013265","journal-title":"Schizophr Res"},{"key":"629_CR55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11\u201319","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"5","key":"629_CR56","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0006-3223(95)00228-9","volume":"38","author":"MP Caligiuri","year":"1995","unstructured":"Caligiuri MP et\u00a0al (1995) Fluctuation of tardive dyskinesia. Biol Psychiatry 38(5):336\u2013339","journal-title":"Biol Psychiatry"},{"issue":"2","key":"629_CR57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0006-3223(91)90042-K","volume":"29","author":"MP Caligiuri","year":"1991","unstructured":"Caligiuri MP et al (1991) Clinical and instrumental assessment of neuroleptic-induced parkinsonism in patients with tardive dyskinesia. Biol Psychiatry 29(2):139\u2013148","journal-title":"Biol Psychiatry"},{"issue":"2","key":"629_CR58","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/JCP.0000000000000277","volume":"35","author":"MP Caligiuri","year":"2015","unstructured":"Caligiuri MP et\u00a0al (2015) A quantitative measure of handwriting dysfluency for assessing tardive dyskinesia. J\u00a0Clin Psychopharmacol 35(2):168\u2013174","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"629_CR59","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002130050320","volume":"132","author":"MP Caligiuri","year":"1997","unstructured":"Caligiuri MP et\u00a0al (1997) Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study #394. Psychopharmacology (Berl) 132(1):61\u201366","journal-title":"Psychopharmacology (Berl)"},{"key":"629_CR60","first-page":"e50852","volume":"81","author":"DJ Dean","year":"2013","unstructured":"Dean DJ et\u00a0al (2013) Handwriting analysis indicates spontaneous dyskinesias in neuroleptic naive adolescents at high risk for psychosis. J\u00a0Vis Exp 81:e50852","journal-title":"J Vis Exp"},{"issue":"5","key":"629_CR61","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.humov.2009.07.007","volume":"28","author":"MP Caligiuri","year":"2009","unstructured":"Caligiuri MP et al (2009) Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. Hum Mov Sci 28(5):633\u2013642","journal-title":"Hum Mov Sci"},{"issue":"1\u20132","key":"629_CR62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.psychres.2009.07.005","volume":"177","author":"MP Caligiuri","year":"2010","unstructured":"Caligiuri MP et\u00a0al (2010) Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics. Psychiatry Res 177(1\u20132):77\u201383","journal-title":"Psychiatry Res"},{"issue":"4\u20135","key":"629_CR63","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.humov.2006.02.004","volume":"25","author":"MP Caligiuri","year":"2006","unstructured":"Caligiuri MP et al (2006) Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism. Hum Mov Sci 25(4\u20135):510\u2013522","journal-title":"Hum Mov Sci"},{"key":"629_CR64","first-page":"CD000459","volume":"2","author":"H Bergman","year":"2018","unstructured":"Bergman H et\u00a0al (2018) Antipsychotic reduction and\/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev 2:CD459","journal-title":"Cochrane Database Syst Rev"},{"issue":"43","key":"629_CR65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21430","volume":"21","author":"H Bergman","year":"2017","unstructured":"Bergman H et al (2017) Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess 21(43):1\u2013218","journal-title":"Health Technol Assess"},{"issue":"8","key":"629_CR66","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/archpsyc.1983.01790070083010","volume":"40","author":"JM Kane","year":"1983","unstructured":"Kane JM et al (1983) Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry 40(8):893\u2013896","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"629_CR67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-198704000-00008","volume":"2","author":"IB Cookson","year":"1987","unstructured":"Cookson IB (1987) The effects of a\u00a050\u202f% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a\u00a0high dose regime. Int Clin Psychopharmacol 2(2):141\u2013149","journal-title":"Int Clin Psychopharmacol"},{"key":"629_CR68","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000408484","volume":"21","author":"DE Casey","year":"1983","unstructured":"Casey DE, Toenniessen LM (1983) Neuroleptic treatment in tardive dyskinesia: can it be developed into a\u00a0clinical strategy for long-term treatment? Mod Probl Pharmacopsychiatry 21:65\u201379","journal-title":"Mod Probl Pharmacopsychiatry"},{"issue":"6","key":"629_CR69","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00002826-199112000-00006","volume":"14","author":"Y Koshino","year":"1991","unstructured":"Koshino Y et al (1991) A long-term outcome study of tardive dyskinesia in patients on antipsychotic medication. Clin Neuropharmacol 14(6):537\u2013546","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"629_CR70","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1600-0447.1992.tb03264.x","volume":"86","author":"R Yassa","year":"1992","unstructured":"Yassa R, Nair NP (1992) A 10-year follow-up study of tardive dyskinesia. Acta Psychiatr Scand 86(4):262\u2013266","journal-title":"Acta Psychiatr Scand"},{"issue":"11","key":"629_CR71","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0033-3182(84)72946-X","volume":"25","author":"R Yassa","year":"1984","unstructured":"Yassa R, Nair V, Schwartz G (1984) Tardive dyskinesia: a\u00a0two-year follow-up study. Psychosomatics 25(11):852\u2013855","journal-title":"Psychosomatics"},{"issue":"Suppl 1","key":"629_CR72","doi-asserted-by":"crossref","first-page":"36S","DOI":"10.1097\/00004714-199502001-00007","volume":"15","author":"G Chouinard","year":"1995","unstructured":"Chouinard G (1995) Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J\u00a0Clin Psychopharmacol 15(Suppl 1):36S\u201344S","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"629_CR73","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.4088\/JCP.v64n1110","volume":"64","author":"YM Bai","year":"2003","unstructured":"Bai YM, Yu SC, Lin CC (2003) Risperidone for severe tardive dyskinesia: a\u00a012-week randomized, double-blind, placebo-controlled study. J\u00a0Clin Psychiatry 64(11):1342\u20131348","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"629_CR74","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1532-5415.1999.tb01595.x","volume":"47","author":"DV Jeste","year":"1999","unstructured":"Jeste DV et\u00a0al (1999) Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J\u00a0Am Geriatr Soc 47(6):716\u2013719","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"629_CR75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00004850-200503000-00003","volume":"20","author":"YM Bai","year":"2005","unstructured":"Bai YM et al (2005) Risperidone for pre-existing severe tardive dyskinesia: a\u00a048-week prospective follow-up study. Int Clin Psychopharmacol 20(2):79\u201385","journal-title":"Int Clin Psychopharmacol"},{"issue":"11","key":"629_CR76","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1176\/appi.ajp.158.11.1931","volume":"158","author":"JY Chen","year":"2001","unstructured":"Chen JY et\u00a0al (2001) Risperidone for tardive dyskinesia. Am J Psychiatry 158(11):1931\u20131932","journal-title":"Am J Psychiatry"},{"issue":"4","key":"629_CR77","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0165-1781(86)90128-9","volume":"19","author":"CC Huang","year":"1986","unstructured":"Huang CC (1986) Comparison of two groups of tardive dyskinesia patients. Psychiatry Res 19(4):335\u2013336","journal-title":"Psychiatry Res"},{"key":"629_CR78","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10401238909149978","volume":"1","author":"ED Peselow","year":"1989","unstructured":"Peselow ED, Angrist BM, Rotrosen J (1989) Changes in tardive dyskinesia after fluphenazine decanoate discontinuation. Ann Clin Psychiatry 1:187\u2013191","journal-title":"Ann Clin Psychiatry"},{"issue":"4","key":"629_CR79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2302\/kjm.34.211","volume":"34","author":"G Yagi","year":"1985","unstructured":"Yagi G, Itoh H (1985) A 10-year follow-up study of tardive dyskinesia\u2014with special reference to the influence of neuroleptic administration on the long-term prognosis. Keio J Med 34(4):211\u2013219","journal-title":"Keio J Med"},{"key":"629_CR80","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ajp.2013.12.016","volume":"8","author":"S Grover","year":"2014","unstructured":"Grover S et\u00a0al (2014) Management of tardive syndromes with clozapine: a\u00a0case series. Asian J Psychiatr 8:111\u2013114","journal-title":"Asian J Psychiatr"},{"issue":"6","key":"629_CR81","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ajp.2013.08.067","volume":"6","author":"N Hazari","year":"2013","unstructured":"Hazari N, Kate N, Grover S (2013) Clozapine and tardive movement disorders: a\u00a0review. Asian J Psychiatr 6(6):439\u2013451","journal-title":"Asian J Psychiatr"},{"key":"629_CR82","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12888-015-0644-1","volume":"15","author":"S Joe","year":"2015","unstructured":"Joe S et al (2015) Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a\u00a0case report. BMC Psychiatry 15:253","journal-title":"BMC Psychiatry"},{"issue":"Suppl B","key":"629_CR83","first-page":"102","volume":"55","author":"CA Tamminga","year":"1994","unstructured":"Tamminga CA et\u00a0al (1994) Clozapine in tardive dyskinesia: observations from human and animal model studies. J\u00a0Clin Psychiatry 55(Suppl B):102\u2013106","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"629_CR84","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4088\/JCP.v65n0516","volume":"65","author":"R Emsley","year":"2004","unstructured":"Emsley R et al (2004) A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J\u00a0Clin Psychiatry 65(5):696\u2013701","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"629_CR85","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4088\/JCP.09m05155yel","volume":"71","author":"HY Chan","year":"2010","unstructured":"Chan HY et al (2010) A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. J\u00a0Clin Psychiatry 71(9):1226\u20131233","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"629_CR86","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4088\/JCP.09m05793yel","volume":"72","author":"SN Caroff","year":"2011","unstructured":"Caroff SN et\u00a0al (2011) Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J\u00a0Clin Psychiatry 72(3):295\u2013303","journal-title":"J Clin Psychiatry"},{"key":"629_CR87","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pnpbp.2012.10.018","volume":"46","author":"CH Cho","year":"2013","unstructured":"Cho CH, Lee HJ (2013) Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry 46:207\u2013213","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"9","key":"629_CR88","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/070674370505000907","volume":"50","author":"HC Margolese","year":"2005","unstructured":"Margolese HC et\u00a0al (2005) Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 50(9):541\u2013547","journal-title":"Can J Psychiatry"},{"issue":"11","key":"629_CR89","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/070674370505001110","volume":"50","author":"HC Margolese","year":"2005","unstructured":"Margolese HC et\u00a0al (2005) Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry 50(11):703\u2013714","journal-title":"Can J Psychiatry"},{"issue":"1","key":"629_CR90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852917000621","volume":"23","author":"SM Stahl","year":"2018","unstructured":"Stahl SM (2018) Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: Reducing dopamine leads to less \u201cgo\u201d and more \u201cstop\u201d from the motor striatum for robust therapeutic effects. Cns Spectr 23(1):1\u20136","journal-title":"Cns Spectr"},{"issue":"8","key":"629_CR91","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.31.8.1051","volume":"31","author":"SW Asher","year":"1981","unstructured":"Asher SW, Aminoff MJ (1981) Tetrabenazine and movement disorders. Neurology 31(8):1051\u20131054","journal-title":"Neurology"},{"issue":"8","key":"629_CR92","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","volume":"156","author":"WG Ondo","year":"1999","unstructured":"Ondo WG, Hanna PA, Jankovic J (1999) Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 156(8):1279\u20131281","journal-title":"Am J Psychiatry"},{"issue":"5","key":"629_CR93","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","volume":"174","author":"RA Hauser","year":"2017","unstructured":"Hauser RA et al (2017) KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 174(5):476\u2013484","journal-title":"Am J Psychiatry"},{"issue":"12","key":"629_CR94","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/mds.26330","volume":"30","author":"CF O\u2019Brien","year":"2015","unstructured":"O\u2019Brien CF et al (2015) NBI-98854, a\u00a0selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord 30(12):1681\u20131687","journal-title":"Mov Disord"},{"issue":"3","key":"629_CR95","doi-asserted-by":"crossref","first-page":"69","DOI":"10.64719\/pb.4366","volume":"47","author":"JM Kane","year":"2017","unstructured":"Kane JM et al (2017) Efficacy of valbenazine (NBI-98854) in treating subjects with tardive dyskinesia and schizophrenia or schizoaffective disorder. Psychopharmacol Bull 47(3):69\u201376","journal-title":"Psychopharmacol Bull"},{"key":"629_CR96","first-page":"CD000458","volume":"1","author":"HG El-Sayeh","year":"2018","unstructured":"El-Sayeh HG et al (2018) Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 1:CD458","journal-title":"Cochrane Database Syst Rev"},{"key":"629_CR97","first-page":"CD000205","volume":"1","author":"H Bergman","year":"2018","unstructured":"Bergman H, Bhoopathi PS, Soares-Weiser K (2018) Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 1:CD205","journal-title":"Cochrane Database Syst Rev"},{"key":"629_CR98","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.colsurfb.2016.11.043","volume":"151","author":"R Cassano","year":"2017","unstructured":"Cassano R et al (2017) Alpha-Tocopheryl linolenate solid lipid nanoparticles for the encapsulation, protection, and release of the omega-3 polyunsaturated fatty acid: in vitro anti-melanoma activity evaluation. Colloids Surf B Biointerfaces 151:128\u2013133","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"10","key":"629_CR99","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0006-3223(93)90044-E","volume":"34","author":"R Miller","year":"1993","unstructured":"Miller R, Chouinard G (1993) Loss of striatal cholinergic neurons as a\u00a0basis for tardive and L\u2011dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 34(10):713\u2013738","journal-title":"Biol Psychiatry"},{"issue":"2","key":"629_CR100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000117742","volume":"6","author":"GB Burnett","year":"1980","unstructured":"Burnett GB et\u00a0al (1980) Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism. Neuropsychobiology 6(2):109\u2013120","journal-title":"Neuropsychobiology"},{"issue":"4\u20136","key":"629_CR101","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0278-5846(82)80151-6","volume":"6","author":"G Chouinard","year":"1982","unstructured":"Chouinard G, Steinberg S (1982) Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry 6(4\u20136):571\u2013578","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"629_CR102","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1176\/ajp.140.2.200","volume":"140","author":"G Gardos","year":"1983","unstructured":"Gardos G, Cole JO (1983) Tardive dyskinesia and anticholinergic drugs. Am J Psychiatry 140(2):200\u2013202","journal-title":"Am J Psychiatry"},{"issue":"8","key":"629_CR103","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/jnnp.37.8.941","volume":"37","author":"HL Klawans","year":"1974","unstructured":"Klawans HL, Rubovits R (1974) Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J\u00a0Neurol Neurosurg Psychiatry 37(8):941\u2013947","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"629_CR104","first-page":"CD000207","volume":"3","author":"I Tammenmaa-Aho","year":"2018","unstructured":"Tammenmaa-Aho I et al (2018) Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 3:CD207","journal-title":"Cochrane Database Syst Rev"},{"key":"629_CR105","first-page":"CD000204","volume":"1","author":"H Bergman","year":"2018","unstructured":"Bergman H, Soares-Weiser K (2018) Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 1:CD204","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"629_CR106","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00004714-199704000-00004","volume":"17","author":"S Angus","year":"1997","unstructured":"Angus S et\u00a0al (1997) A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J\u00a0Clin Psychopharmacol 17(2):88\u201391","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"629_CR107","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1176\/jnp.1.1.96","volume":"1","author":"R Ankenman","year":"1989","unstructured":"Ankenman R (1989) The combination of amantadine and neuroleptics plus time may cure tardive dyskinesia. J\u00a0Neuropsychiatry Clin Neurosci 1(1):96\u201397","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"4","key":"629_CR108","first-page":"173","volume":"56","author":"O Freudenreich","year":"1995","unstructured":"Freudenreich O, McEvoy JP (1995) Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics. J\u00a0Clin Psychiatry 56(4):173","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"629_CR109","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","volume":"33","author":"S Pappa","year":"2010","unstructured":"Pappa S et al (2010) Effects of amantadine on tardive dyskinesia: a\u00a0randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 33(6):271\u2013275","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"629_CR110","first-page":"167","volume":"56","author":"H Silver","year":"1995","unstructured":"Silver H, Geraisy N, Schwartz M (1995) No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a\u00a0double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J\u00a0Clin Psychiatry 56(4):167\u2013170","journal-title":"J Clin Psychiatry"},{"key":"629_CR111","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1192\/bjp.155.1.55","volume":"155","author":"TG Dinan","year":"1989","unstructured":"Dinan TG, Kohen D (1989) Tardive dyskinesia in bipolar affective disorder: relationship to lithium therapy. Br J\u00a0Psychiatry 155:55\u201357","journal-title":"Br J\u00a0Psychiatry"},{"issue":"3","key":"629_CR112","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000117629","volume":"4","author":"A Jus","year":"1978","unstructured":"Jus A et al (1978) Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study. Neuropsychobiology 4(3):140\u2013149","journal-title":"Neuropsychobiology"},{"issue":"5","key":"629_CR113","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1176\/ajp.132.5.560","volume":"132","author":"FA Reda","year":"1975","unstructured":"Reda FA, Escobar JI, Scanlan JM (1975) Lithium carbonate in the treatment of tardive dyskinesia. Am J Psychiatry 132(5):560\u2013562","journal-title":"Am J Psychiatry"},{"issue":"2","key":"629_CR114","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.euroneuro.2007.07.004","volume":"18","author":"PN Harten van","year":"2008","unstructured":"van Harten PN et\u00a0al (2008) Evidence that lithium protects against tardive dyskinesia: the Curacao Extrapyramidal Syndromes Study VI. Eur Neuropsychopharmacol 18(2):152\u2013155","journal-title":"Eur Neuropsychopharmacol"},{"key":"629_CR115","first-page":"CD000209","volume":"1","author":"K Soares-Weiser","year":"2018","unstructured":"Soares-Weiser K, Maayan N, Bergman H (2018) Vitamin E for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 1:CD209","journal-title":"Cochrane Database Syst Rev"},{"key":"629_CR116","first-page":"CD010501","volume":"4","author":"AO Adelufosi","year":"2015","unstructured":"Adelufosi AO, Abayomi O, Ojo TM (2015) Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 4:CD10501","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"629_CR117","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40265-018-0874-x","volume":"78","author":"N Niemann","year":"2018","unstructured":"Niemann N, Jankovic J (2018) Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs 78(5):525\u2013541","journal-title":"Drugs"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-018-0629-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-018-0629-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-018-0629-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:49:24Z","timestamp":1775249364000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-018-0629-7"}},"subtitle":["Sp\u00e4tdyskinesien","Tardive dyskinesia"],"short-title":[],"issued":{"date-parts":[[2018,10,19]]},"references-count":117,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1007\/s00115-018-0629-7","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,19]]},"assertion":[{"value":"19 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0Hirjak, K.M.\u00a0Kubera, S.\u00a0Bienentreu, P.A.\u00a0Thomann und R.C.\u00a0Wolf geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}